Nascent Biotech and Manhattan BioSolutions Collaborate to Explore Pritumumab Antibody-Drug Conjugates [Yahoo! Finance]
NASCENT BIOTECH INC (NBIO)
NASDAQ:AMEX Investor Relations:
nascentbiotech.com/investor-relations
Company Research
Source: Yahoo! Finance
clinical-stage biotechnology company pioneering the development of monoclonal antibodies for the treatment of various cancers and viral infections, announced today it has entered into a research collaboration agreement with Manhattan BioSolutions, Inc. (Manhattan Bio), an emerging biotech company focused on precision biologics, to explore antibody-drug conjugates (ADCs) using Nascent's lead clinical candidate pritumumab (PTB) as the tumor-targeting antibody element. Pritumumab (PTB) is a natural human antibody. This monoclonal antibody targets extracellular form of vimentin, a protein that has been linked to cancer growth and metastasis and is overexpressed in both brain and pancreatic cancers as well as other hard tumor cancers. PTB is a targeted immunotherapy that binds to vimentin in tumors and recruits the immune system to eliminate cancer cells. PTB has demonstrated a promising safety profile and preliminary efficacy in completed Phase I study in glioblastoma patients. Nascent
Show less
Read more
Impact Snapshot
Event Time:
NBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NBIO alerts
High impacting NASCENT BIOTECH INC news events
Weekly update
A roundup of the hottest topics
NBIO
News
- Nascent Prepares for Pivotal Phase II Research with Fresh Manufacturing Run [Yahoo! Finance]Yahoo! Finance
- Nascent Prepares for Pivotal Phase II Research with Fresh Manufacturing RunAccesswire
- Nascent Collaborates With Hypospray Pharma on Proprietary Transdermal Delivery System [Yahoo! Finance]Yahoo! Finance
- Nascent Collaborates With Hypospray Pharma on Proprietary Transdermal Delivery SystemAccesswire
- Nascent Biotech and Manhattan BioSolutions Collaborate to Explore Pritumumab Antibody-Drug ConjugatesAccesswire
NBIO
Sec Filings
- 4/10/24 - Form 4
- 4/10/24 - Form 4
- 4/10/24 - Form 4
- NBIO's page on the SEC website